97 related articles for article (PubMed ID: 6593896)
21. Pharmacokinetics of 6-mercaptopurine (6MP) in the monkey. I. Disposition from plasma and cerebrospinal fluid following iv bolus.
Narang PK; Chatterji DC; O'Neill D; Poplack DG
Drug Metab Dispos; 1983; 11(1):5-9. PubMed ID: 6132796
[TBL] [Abstract][Full Text] [Related]
22. Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results.
Janka GE; Mack R; Helmig M; Haas RJ; Bidlingmaier F
Oncology; 1984; 41(4):225-32. PubMed ID: 6589560
[TBL] [Abstract][Full Text] [Related]
23. Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Barcelos A; Dubbelman B; De Abreu R; Brouwer C; Bökkerink JP; de Haas V; de Groot-Kruseman H; Jansen G; Kaspers GL; Cloos J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):422-33. PubMed ID: 24940700
[TBL] [Abstract][Full Text] [Related]
24. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
[TBL] [Abstract][Full Text] [Related]
25. 6-mercaptopurine: high-dose 24-h infusions in goats.
Schouten TJ; De Abreu RA; Schretlen ED; van Baal JM; van Leeuwen MB; de Vaan GA
J Cancer Res Clin Oncol; 1986; 112(1):61-6. PubMed ID: 3733868
[TBL] [Abstract][Full Text] [Related]
26. Role of base-excision repair in the treatment of childhood acute lymphoblastic leukaemia with 6-mercaptopurine and high doses of methotrexate.
Stanczyk M; Sliwinski T; Trelinska J; Cuchra M; Markiewicz L; Dziki L; Bieniek A; Bielecka-Kowalska A; Kowalski M; Pastorczak A; Szemraj J; Mlynarski W; Majsterek I
Mutat Res; 2012 Jan; 741(1-2):13-21. PubMed ID: 22064329
[TBL] [Abstract][Full Text] [Related]
27. Unusual skin rash following withdrawal of oral 6-mercaptopurine in children with leukemia.
Kirk JA; Rogers M; Menser MA; Bergin M; Dalla-Pozza L; Stevens MM
Med Pediatr Oncol; 1987; 15(5):281-4. PubMed ID: 3477681
[TBL] [Abstract][Full Text] [Related]
28. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
van Kooten Niekerk PB; Schmiegelow K; Schroeder H
Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
[TBL] [Abstract][Full Text] [Related]
29. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine in rabbits.
Tterlikkis L; Day JL; Brown DA; Schroeder EC
Cancer Res; 1983 Apr; 43(4):1675-9. PubMed ID: 6682007
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment.
Schrøder H; Clausen N; Ostergaard E; Pressler T
Cancer Chemother Pharmacol; 1986; 16(2):190-3. PubMed ID: 3456283
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
32. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia.
Bostrom B; Erdmann G
Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):80-6. PubMed ID: 8447563
[TBL] [Abstract][Full Text] [Related]
33. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)].
Nakamura T; Ueda T; Uchida M
Gan To Kagaku Ryoho; 1992 Mar; 19(3):409-20. PubMed ID: 1543370
[TBL] [Abstract][Full Text] [Related]
34. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.
Israeli E; Goldin E; Fishman S; Konikoff F; Lavy A; Chowers Y; Melzer E; Lahat A; Mahamid M; Shirin H; Nussinson E; Segol O; Ya'acov AB; Shabbat Y; Ilan Y
Clin Exp Immunol; 2015 Aug; 181(2):362-72. PubMed ID: 25846055
[TBL] [Abstract][Full Text] [Related]
35. Preferential inhibition of xanthine oxidase by 2-amino-6-hydroxy-8-mercaptopurine and 2-amino-6-purine thiol.
Kalra S; Jena G; Tikoo K; Mukhopadhyay AK
BMC Biochem; 2007 May; 8():8. PubMed ID: 17511860
[TBL] [Abstract][Full Text] [Related]
36. The pharmacology of orally administered chemotherapy. A reappraisal.
Poplack DG; Balis FM; Zimm S
Cancer; 1986 Jul; 58(2 Suppl):473-80. PubMed ID: 3459570
[TBL] [Abstract][Full Text] [Related]
37. Methotrexate-vindesine association in leukemia: pharmacokinetic study.
Tubiana N; Lena N; Barbet J; Imbert AM; Lejeune C; Maraninchi D; Sainty D; Sebahoun G; Gastaut JA; Cano JP
Med Oncol Tumor Pharmacother; 1985; 2(2):99-102. PubMed ID: 3864001
[TBL] [Abstract][Full Text] [Related]
38. Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
Pediatr Blood Cancer; 2016 Apr; 63(4):712-5. PubMed ID: 26878433
[TBL] [Abstract][Full Text] [Related]
39. Active transport of methotrexate from cerebrospinal fluid in humans.
Bode U; Magrath IT; Bleyer WA; Poplack DG; Glaubiger DL
Cancer Res; 1980 Jul; 40(7):2184-7. PubMed ID: 7388786
[TBL] [Abstract][Full Text] [Related]
40. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
